A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.

Healthy Clinical Trial

Official title:

Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG3067, the Combination of GLPG3067 and GLPG2222, and the Combination of GLPG3067, GLPG2222 and GLPG2737 in Healthy Female Subjects, Including a Relative Bioavailability and Food Effect Part for Single Dose of GLPG3067.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03128606
• Other study ID #: GLPG3067-CL-101
• Status: Completed
• Phase: Phase 1
• First received: April 21, 2017
• Last updated: April 9, 2018
• Start date: March 28, 2017
• Est. completion date: February 20, 2018

Study information

• Verified date: April 2018
• Source: Galapagos NV
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a First-in-Human, Phase I, randomized, double-blind, placebo-controlled, single center study, evaluating single and multiple ascending oral doses of GLPG3067 and the combination of GLPG3067 and GLPG2222 and the combination of GLPG3067,GLPG2222 and GLPG2737 given for 14 days in healthy women of non-childbearing potential.

The purpose of the study is to evaluate the safety and tolerability of single ascending oral doses and multiple ascending oral doses of GLPG3067 given to healthy women of non-childbearing potential compared to placebo, as well as of multiple oral doses of the combination of GLPG3067/GLPG2222 compared to matching placebo for each compound and multiple oral doses of the combination of GLPG3067/GLPG2222/GLPG2737 compared to matching placebo for each compound.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 81
• Est. completion date: February 20, 2018
• Est. primary completion date: February 20, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Female subject between 18-70 years of age, inclusive, on the date of signing the informed consent form (ICF).

• Be of non-childbearing potential defined as surgically sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy), or post-menopausal (at least 12 consecutive months without menstruation, without an alternative medical cause [including hormone replacement therapy]).

• Have a body mass index between 18-30 kg/m2, inclusive.

• Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead triplicate electrocardiogram (ECG), and clinical safety laboratory tests prior to the initial study drug administration.

• Discontinuation of all medications (including over-the-counter and/or prescription medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements, and hormonal replacement therapy for postmenopausal subjects) except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) at least 2 weeks prior to the first study drug administration.

Exclusion Criteria:

• Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.

• Clinically significant symptoms or illness in the 3 months before screening.

• Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.

• Any laboratory result considered by the investigator as clinically significant prior to study drug administration.

• Creatinine clearance =80 mL/min using the Cockcroft-Gault formula for subjects aged =50 years, or creatinine clearance =70 mL/min using the Cockcroft-Gault formula for subjects aged >50 years. A 24-hour urine collection to determine the actual value may be performed to confirm creatinine clearance if required.

• Clinically significant abnormalities of vital signs at screening.

• Clinically relevant abnormalities detected on ECG regarding either rhythm or conduction (e.g. QT interval corrected for heart rate using Fridericia's formula [QTcF] >470 ms) or a known long QT syndrome. A first degree heart block or sinus arrhythmia will not be considered as a significant abnormality.

• Participation in a drug, drug and device delivery system or combination, or biologic investigational research study within 8 weeks or 5 times the half-life of the investigational drug, if the half-life is known (whichever is longer) prior to initial study drug administration. Subjects who have been dosed previously with GLPG3067 in a clinical trial are allowed to participate Part 4 of this study as long as they completed their last follow-up visit or a washout period of 5 times the half-life of GLPG3067 (whichever is longer) after the last study drug administration is respected.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• GLPG3067 single dose
GLPG3067 oral suspension, single ascending doses, daily
• Placebo single dose
Placebo, oral suspension, daily
• GLPG3067 multiple dose
GLPG3067 oral suspension, multiple ascending doses, daily for 14 days
• Placebo multiple dose
Placebo, oral suspension, daily for 14 days
• GLPG3067 oral suspension
GLPG3067 oral suspension, single dose, daily
• GLPG3067 oral tablet
GLPG3067 oral tablet, single dose, daily
• GLPG3067/GLPG2222 multiple dose
GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days
• GLPG3067/GLPG2222 Placebo multiple dose
GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days
• GLPG3067/GLPG2222/GLPG2737 multiple dose
GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days
• GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose
GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days

Locations

Country	Name	City	State
Belgium	SGS LSS Clinical Pharmacology Unit Antwerp	Antwerp

Sponsors (1)

Lead Sponsor	Collaborator
Galapagos NV

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change versus placebo in the proportion of subjects with adverse events	To assess safety and tolerability of single ascending doses, multiple ascending doses of GLPG3067 alone, or in combination with GLPG2222, or in combination with GLPG2222 and GLPG2737 versus placebo in healthy subjects	Between screening and 14 days after the last dose
Secondary	Maximum observed plasma concentration of GLPG3067 (Cmax) given alone or in combination with GLPG2222 or in combination with GLPG2222 and GLPG2737	To characterize pharmacokinetics of GLPG3067 after a single oral dose and of GLPG3067, GLPG2222, and GLPG2737 after multiple oral doses in healthy subjects	Between Day 1 predose and 10 days after the last dose
Secondary	Area under the plasma concentration-time curve of GLPG3067 (AUC0-t) given alone or in combination with GLPG2222 or in combination with GLPG2222 and GLPG2737	To characterize pharmacokinetics of GLPG3067 after a single oral dose and of GLPG3067, GLPG2222, and GLPG2737 after multiple oral doses in healthy subjects	Between Day 1 predose and 10 days after the last dose
Secondary	Ratio of 4-beta-hydroxycholesterol/cholesterol in plasma after multiple oral doses in healthy subjects	To assess the potential for CYP3A4 interaction with GLPG3067, GLPG3067 and GLPG2222, or GLPG3067 and GLPG2222 and GLPG2737	Day 1 predose and Day 14
Secondary	Maximum observed plasma concentration of GLPG3067 (Cmax) given alone in fed state	To assess the relative bioavailability of GLPG3067 when given as a single dose of oral suspension or an oral tablet both administered in fed state	Between Day 1 predose and 10 days after the last dose
Secondary	Concentration in plasma observed at 24 hours post dose (C24h) of GLPG3067 given alone in fed state	To assess the relative bioavailability of GLPG3067 when given as a single dose of oral suspension or an oral tablet both administered in fed state	Between Day 1 predose and 10 days after the last dose
Secondary	Area under the plasma concentration-time curve of GLPG3067 (AUC0-t) given alone in fed state	To assess the relative bioavailability of GLPG3067 when given as a single dose of oral suspension or an oral tablet both administered in fed state	Between Day 1 predose and 10 days after the last dose
Secondary	Maximum observed plasma concentration of GLPG3067 (Cmax) given alone in fasted state	To assess the effect of food on the pharmacokinetics of GLPG3067 when given under fasted versus fed conditions	Between Day 1 predose and 10 days after the last dose
Secondary	Concentration in plasma observed at 24 hours post dose (C24h) of GLPG3067 given alone in fasted state	To assess the effect of food on the pharmacokinetics of GLPG3067 when given under fasted versus fed conditions	Between Day 1 predose and 10 days after the last dose
Secondary	Area under the plasma concentration-time curve of GLPG3067 (AUC0-t) given alone in fasted state	To assess the effect of food on the pharmacokinetics of GLPG3067 when given under fasted versus fed conditions	Between Day 1 predose and 10 days after the last dose